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Background: Chronic obstructive pulmonary disease (COPD) is characterized by an irreversible
chronic airflow obstruction and by an accelerated decline in lung function. Elevated circulating
levels of C-reactive protein (CRP) and interleukin-6 (IL-6), both markers of systemic inflamma-
tion, have been found in COPD. Their possible associations with chronic airflow obstruction
have mostly been evaluated in highly selected patient samples. Our objective was to evaluate
the association between postbronchodilator lung function CRP and IL-6 in a randomly selected
sample of the Icelandic population, 40 years and older, while adjusting for gender, age,
smoking, and body weight.
Methods: Serum CRP and IL-6 values were measured among participants in the Burden of
Obstructive Lung Disease (BOLD) study.
Results: Of the 938 subjects invited a total of 403 men and 355 women participated (response
rate 81%) in the study. Their mean age (SD) was 57.7 (12.7) years. Both CRP and IL-6 were
independently related to lower FEV1 and FVC values. Individuals in the highest quartiles of CRP
and IL-6 had a 7.5% and 3.9%, respectively, lower FEV1% than predicted after adjustment for
smoking, age, and body weight. High CRP levels were more strongly related to lower FEV1
levels in men (11.4%) than in women (0.4%).t of Respiratory Medicine and Sleep (E7), Landspitali University Hospital, 108 Reykjavik, Iceland.
obile); fax: þ354 5436568.
itali.is (G. Gudmundsson).
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to lower spirometric values. The association with CRP was stronger in men than in women. This
finding underscores the possible importance of systemic inflammation in irreversible airflow
limitation.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a disease
characterized by airflow limitation and accelerated decline
in lung function.1 COPD is accompanied with signs of
systemic inflammation.2,3 Circulating levels of several
proinflammatory markers such as C-reactive protein (CRP)
and interleukin-6 (IL-6) have been found to be elevated in
the blood of selected patient populations with COPD.4,5
Patients with restrictive lung disease have also been found
to have elevated blood levels of CRP.6
Elevated CRP and IL-6 levels are associated with an
increased risk of future myocardial infarction and coronary
artery disease,7,8 but there are only fewer studies on the
relationship between IL-6 and COPD than CRP and COPD. A
cohort of 148 COPD patients was followed for 2.91 years
and IL-6 sputum concentration was found to rise by 9 pg/
mL/year as FEV1 declined by 40.2 mL/year. Those patients
who had more frequent exacerbations had a faster rise in
sputum IL-6 over time.9 BMI had as strong an association
with CRP levels as overweight (BMI 25e29.9), and obese
subjects (BMI 30) were more likely to have elevated CRP
than subjects of normal weight.10
We have previously,11 in a multicentre study on pop-
ulation-based cohorts of young to middle-aged subjects
(age 28e56 years), shown that CRP is negatively associated
with FEV1 and that this correlation was significantly larger
in men than in women. Further, the rate of decline in lung
function during the 8.3 years of follow-up was strongly
correlated with high CRP levels among men. In general little
is known about the relationship between airflow limitation,
CRP and IL-6 in the middle-aged to older general population
since most previous studies have been based on highly
selected patient samples. Furthermore limited information
is available on gender differences in the relationship
between airflow limitation and markers of inflammation.
The aim of this study was to therefore evaluate the
association between postbronchodilators FEV1, FVC, CRP
and IL-6 in a randomly selected sample of the Icelandic
population.Materials and methods
Study design
The Burden of Lung Disease Initiative (BOLD) is an inter-
national study on the prevalence of COPD that has recently
been described in detail.12 The study was conducted in
Reykjavik, Iceland, for over a period of 10 months from
December 2004 to September 2005. The target population
consisted of residents aged 40 years or older living in the
capital of Reykjavik and the surrounding suburbs, an areawith a population of about 180,000 individuals (compared
to 300,000 for all of Iceland). Starting with the national
registry, all age-eligible Icelandic citizens who were regis-
tered in Reykjavik and surrounding suburbs were identified.
This sample consisted of 35,228 men and 38,163 women.
Study participants (1000 subjects) were then selected using
a simple random sample, not stratified by gender. After
sampling it was found that 62 individuals did not fulfill the
inclusion criteria. The final study group consisted of 938
individuals. After written informed consent was obtained
subjects answered the standardized questionnaires
administered by the trained interviewers, underwent
spirometry tests, and a blood sample was obtained. The
protocol was approved by the National Bioethics Committee
of Iceland (04-080).
Spirometry and definitions
FEV1 and FVC values were obtained by spirometry. Testing
was conducted with the participant in a sitting position
wearing a nose clip and a disposable mouthpiece using the
NDD Easy One (ndd Medizintechnik, Zurich, Switzerland)
spirometer. Pre- and postbronchodilator tests were per-
formed.12 In accordance with the BOLD protocol individuals
who recently had a cold/upper respiratory infection were
asked to participate later because of the effect on
spirometry. BOLD uses the prediction equations for Cauca-
sian adult men and women derived from the third United
States National Health and Nutrition Examination Survey
(NHANES III) as its primary reference equations for all
participants.13
Blood samples and measurements
Blood was drawn from the antecubital vein of the seated
subjects. Specimens were collected in SSTs from Greiner
(Kremsmunster, Austria). Serum IL-6 concentrations were
measured with enzyme-linked immunosorbent assays, using
reagents obtained from IBL (Hamburg, Germany). The
lower detection limit of the IL-6 assay was 0.074 pg/mL.
CRP concentrations were measured on a Kone 30 analyser
using a commercially available latex-enhanced immuno-
turbidimetric assay from Roche Diagnostic Systems (Man-
nheim, Germany). The lower detection limit of the assay
was 0.1 mg/L.
Statistical analyses
All statistics were calculated with STATA software, version
intercooled STATA 8.0 for Windows (Stata Corporation,
College Station, Texas). Subjects were divided into four
groups on the basis of the quartile distribution of the CRP
values (<0.75, 0.75e1.27, 1.27e3.25, >3.25) and IL-6
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Figure 1 Association between CRP and IL-6 (median: 10, 25,
75 and 90th percentile).
1550 S.J. Thorleifsson et al.values (<1.51, 1.51e2.82, 2.82e4.69 and >4.69 pg/mL).
Log-transformed values of CRP were used to analyse the
relationship between CRP and IL-6 and gender, pack year
and BMI. Simple linear regression and the Chi-squared test
were used in the univariate analyses, while logistic
regression and multiple linear regression were used to
perform multivariable analyses. Tests for interaction were
carried out to detect the possible differences regarding the
association between the inflammatory markers and the lung
function between men and women as well as for BMI groups
and smoking history. A p-value less than 0.05 was regarded
as statistically significant.
Results
Of the 938 subjects invited a total of 403 men and 355
women (47%) participated (response rate 81%) in the study.
All except three, had acceptable postbronchodilator
spirometry. Of the 180 non-responders, partial data were
collected from 13 individuals, 85 refused to participate but
answered a minimal data questionnaire, and 49 refused to
participate at all. There was no significant difference
between the responders and non-responders regarding age,
smoking status or health. However, there was a significant
difference in gender with proportionally more menTable 1 Inflammatory markers and lung function (mean (95% C
CRP (mg/L) <0.75
0.75e1.27
1.27e3.25
>3.25
ptrend-value
IL-6 (pg/mL) <1.51
1.51e2.82
2.82e4.69
>4.69
ptrend-valueparticipating (pZ 0.01). The total response rate was 81%,
ranging from 69% to 89% in different age groups, with the
lowest among women aged 70 years and older and the
highest among men aged 40e49 years.
Altogether, 746 blood samples were successfully ana-
lysed. A significant association was found between CRP and
IL-6 (Fig. 1). Higher levels of CRP and IL-6 were associated
with lower FEV1 and FVC values (Table 1).
The association between lower lung function and higher
CRP remained significant after adjusting for age, sex,
smoking, BMI and IL-6 (Fig. 2). Corresponding analyses with
IL-6 showed that values in the highest IL-6 quartile were
associated with lower FEV1 and FVC values (Fig. 3). CRP
and IL-6 levels were both positively associated with BMI
(Table 2).
CRP and IL-6 were also positively associated with pack
years (p< 0.001 and pZ 0.03, respectively). No significant
associations were found between the inflammatory markers
and age or sex.
A significant gender interaction was found in the asso-
ciation between CRP and FEV1 (pZ 0.004) and CRP and FVC
(pZ 0.04) with significant associations in men but not in
women (Table 3), whereas no corresponding interaction
was found in relationship to IL-6. No significant interaction
was found in relation to smoking or BMI.
Individuals with both IL-6 and CRP in the highest quartile
(nZ 79) had a lower FEV1 and FVC value e 10.5 (15.7,
5.2)% and 10.3 (14.6, 5.9)%, respectively, compared
to those with IL-6 and CRP in the lowest quartiles after
adjustment for age, sex, BMI, pack years and current
smoking.
Discussion
The main finding of this study was that higher levels of
circulating CRP and IL-6 were independently related to
lower FEV1 and FVC values in a population-based sample of
Icelanders who were 40 years and older. There was
a gender difference in that the relationship between FEV1
and CRP was stronger in men than in women. This has not
been shown in previous studies.
In our study CRP and IL-6 were both positively associated
with BMI and pack years. We have previously reported such
a strong association between CRP, smoking and BMI inI)).
FEV1% pred FVC% pred
97.4 (95.1e99.6) 99.0 (97.2e101)
94.2 (92.0e96.5) 95.3 (93.4e97.2)
92.6 (90.5e94.7) 93.4 (91.6.e95.3)
88.4 (86.0e90.8) 89.6 (87.7e91.6)
<0.0001 <0.0001
94.6 (92.1e97.0) 96.5 (94.5e98.4)
95.5 (93.3e97.7) 96.6 (94.8e98.4)
93.7 (91.5e95.9) 94.4 (92.6e96.3)
88.8 (86.5e91.1) 89.8 (89.9e91.7)
<0.0001 <0.0001
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Figure 2 Association between lung function and quartiles of
CRP. Subjects in the first quartile were the reference group.
The association was adjusted for age, sex, BMI, pack years,
current smoking and IL-6.
Table 2 Inflammatory markers and BMI (geometric means
(95% CI)).
CRP (mg/L) IL-6 (pg/mL)
BMI (kg/m2)
<20 0.7 (0.3e2.1) 2.6 (1.1e6.0)
20e25 1.0 (0.9e1.2) 2.4 (2.1e2.8)
25e30 1.3 (1.2e1.5) 2.7 (2.4e3.0)
>30 2.2 (1.9e2.5) 3.9 (3.4e4.5)
Ptrend-value <0.0001 0.006
Chronic airflow obstruction and markers of systemic inflammation 1551multicentre epidemiological study based on young and
middle-aged adults from Uppsala, Reykjavik and Tartu.14
Shaaban et al. also reported similar findings from a general
population in France.15 This was also true when they fol-
lowed the group longitudinally for over a period of 8.5
years. In our study a significant association was found
between CRP and IL-6 levels. This is not surprising given
how closely these markers are associated with the inflam-
matory responses of the body and the fact that CRP is
produced by hepatocytes under the control of IL-6.16
Higher levels of CRP and IL-6 were associated with lower
FEV1 and FVC values. Such association has been described
before with FEV1.
2,4,5 A report by Mannino et al. showed
that elevation in CRP, both in patients with obstructive and
restrictive lung diseases, had an association with FVC.6 A
study by Engstrom et al. also found a relationship with
FVC.17 The association between lower lung function and
higher CRP remained significant after adjusting for age,
sex, smoking, BMI and IL-6. These results are similar to
many other studies, both based on patient populations with-10
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Figure 3 Association between lung function and quartiles of
IL-6. Subjects in the first quartile were the reference group.
The association was adjusted for age, sex, BMI, pack years,
current smoking and CRP.COPD and general populations where COPD has been iden-
tified by spirometric values.2,4e6,11 In our study IL-6 was
significantly related both to proportionally lower FEV1 and
FVC values, and this association was still significant after
adjustment for age and BMI. IL-6 has been shown to be
higher in COPD patients in other studies2 and related to
reduced lung function. No gender differences were found in
relationship to IL-6.
We found a significant gender difference in the associ-
ation between CRP, FEV1 and FVC, with gender being
significant in men and not in women. This is a finding which
we have also noted in a youngeremiddle-aged cohort.11
Hormonal differences might explain the gender difference
as a study by Nakhai Pour et al. showed that levels of
estradiol were significantly associated with CRP among
middle-aged and older men.18 Van Pottelbergh et al.,
however, found no correlation between testosterone or
estradiol levels and CRP in healthy middle-aged men19 and
Karadag et al. found no relationship between testosterone
or estradiol and IL-6 in patients with COPD.20 Weight-
related or smoking-related effects are also other possibili-
ties that could explain gender differences.21 A gender
difference in the association between IL-6, FEV1 and FVC
was not found. This might have several explanations. This
might be due to different fat distribution between males
and females or due to genetic differences.16
Individuals with both CRP and IL-6 in the highest quartile
had 10.3% lower FEV1 and FVC values compared to those in
the lowest quartiles after adjustment for age, sex, BMI,
pack years and current smoking. A study based on The
Framingham Heart Study population found that a 1-SD
higher concentration of CRP was associated with an FEV1
that was 46 mL lower.4 In our study individuals with IL-6 in
the highest quartile had FEV1 and FVC values that were
10.5% lower than in those with IL-6 in the lowest quartiles
after adjustment for age, sex, BMI, pack years and current
smoking. The Framingham Heart Study found that a 1-SD
higher concentration of IL-6 was associated with a 41-mL
lower FEV1 and a borderline 15% higher odds of COPD.
4
The present study has several advantages. Firstly,
subjects were recruited from a well-defined population,
represented a single ethnic group and were aged 40 years
and older. The high participation rate should reflect the
country’s general population. Approximately the same
number of men and women participated. Minimal differ-
ences were found between the responders and the non-
responders. An international well-standardized protocol
was used with excellent training of staff.12 All spirometry
testings were sent to a quality control centre.12 Since the
air pollution in Iceland is very low22 it is fairly easy to
Table 3 Association between lung function and quartiles of CRP in men and women subjects in the first quartile of the
reference group.
Men Women
FEV% pred <0.75 0 0
0.75e1.27 4.8 (8.8, 0.9) 0.7 (5.7, 4.3)
1.27e3.25 6.7 (10.9, 2.5) 0.3 (5.1, 4.3)
>3.25 11.4 (15.7, 7.1) 0.4 (5.3, 4.5)
FVC% pred <0.75 0 0
0.75e1.27 4.0 (7.4, 0.6) 1.4 (5.4, 2.6)
1.27e3.25 6.9 (10.5, 3.3) 0.5 (4.3, 3.3)
>3.25 9.5 (13.3, 5.8) 3.6 (7.5, 0.4)
The association was adjusted for age, sex, BMI, pack years and current smoking.
1552 S.J. Thorleifsson et al.explore the effects of cigarette smoke on lungs. Reykjavik
also has low levels of airborne allergens23 and no major
industries except for an aluminium smelting plant approx-
imately 20 km south-west of the city centre. However,
previous studies have shown that both active and passive
cigarette smoke exposures in Iceland have been among the
highest in northern Europe,24 and worldwide, Icelandic
women lead in the prevalence of ‘‘ever smoking’’.12
There are several limitations to this study. A single IL-6
and CRP measurement per person was done, which may not
accurately reflect long-term inflammation status. However,
the substantial biological variability of CRP levels was
reduced by using a high-sensitivity method for CRP analysis.
The fact that we did not exclude subjects with a CRP lev-
el> 10 mg/L might have influenced the results. However,
only 16 individuals of a total of 746 had CRP levels higher
than 10 mg/L and the highest value measured was under
20 mg/L, probably because only non-infected subjects were
investigated. The study was performed during a 10-month
period. Normally there is not much seasonal variation in
CRP and IL-6 levels16 and no significant difference was
found in CRP or IL-6 levels between subjects examined in
the darker or lighter part of the year (data not shown).
Respiratory infection could also have influenced our results
but the examination was delayed until recovery, if the
study subject had symptoms/signs of infection. This should
have minimized the effects of infection or other causes of
exacerbations on CRP and IL-6 values. Obesity and smoking
are associated with signs of systemic inflammation.5,7,8 We
therefore adjusted for these factors in our study. The
effects of these factors should therefore be minimal when
evaluating the relationship between decreased lung func-
tion and markers of systemic inflammation.
The relationship between markers of inflammation and
local intrapulmonary processes that result in chronic
airflow obstruction is not well understood.2 Whether the
systemic inflammation contributes to the development of
irreversible airflow obstruction or is an epiphenomenon is
unknown. We did not control for cardiovascular risk factors
in our study. Therefore we cannot exclude the possibility
that unknown cardiovascular risk factors might have caused
some changes in IL-6 and CRP.25
In this population-based study of Icelanders aged 40
years and older we found that higher levels of circulating
CRP and IL-6 were independently related to lower FEV1 andFVC values. There was a gender difference in that the
relationship between FEV1 and CRP was stronger in men
than in women. This has not been shown before. These
results warrant further studies.
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